Investment Rating - The investment rating for the company is "Buy" with a target price of RMB 12.70 [1][4]. Core Views - The company reported Q3 revenue of RMB 5.9 billion, a year-over-year decrease of 2% and a quarter-over-quarter decrease of 1%. However, the net profit attributable to the parent company was RMB 1.26 billion, showing a year-over-year increase of 141% and a quarter-over-quarter increase of 68% [1]. - The company’s net profit for the first three quarters of 2025 reached RMB 30.3 billion, a year-over-year increase of 52%, driven by the acquisition of an overseas company which contributed approximately RMB 7.8 billion to the profit [1][4]. - The report anticipates a recovery in the amino acid market, supported by increased penetration in the aquaculture sector and a favorable demand outlook due to reduced soybean meal usage [1][3]. Summary by Sections Financial Performance - For the first three quarters of 2025, the feed amino acids revenue was RMB 8.19 billion, down 2% year-over-year, while lysine sales increased despite price declines. The average prices for lysine and threonine were RMB 8.5/kg and RMB 10.0/kg, reflecting year-over-year decreases of 16% and 5% respectively [2]. - The overall gross margin improved by 2.4 percentage points to 21.3% due to lower raw material costs [2]. Market Outlook - The prices for key products such as lysine and threonine are currently at low levels, but demand is expected to recover as aquaculture penetration increases and consumer demand rebounds [3]. - The company is expanding its product line through acquisitions, which will enhance its high-value pharmaceutical amino acid offerings and support its international expansion strategy [3]. Profit Forecast and Valuation - The net profit forecast for 2025 has been adjusted down to RMB 3.54 billion, a 3% decrease from previous estimates, while maintaining projections of approximately RMB 3.6 billion and RMB 3.8 billion for 2026 and 2027 respectively [4]. - The expected earnings per share (EPS) for 2025 is RMB 1.26, with a projected price-to-earnings (P/E) ratio of 11x for 2025 [4][8].

Group 1: Company Strategy and Operations - The company is actively expanding its raw material import channels to mitigate procurement risks due to international environmental changes [2] - The Thai factory is part of the company's overseas strategy, expected to be completed in the second half of the year, with an anticipated production capacity of 10,000 tons of pea protein [3] - The company is focusing on new applications for pea protein, particularly in high-end pet food and emerging markets in Asia [2] Group 2: Financial and Investment Insights - The company has not yet initiated its share repurchase plan as the loan funds for the buyback have not been received [3] - In 2024, the company's R&D expenses amounted to 65.67 million yuan, with multiple patents granted and participation in key provincial R&D projects [4] - The company expresses confidence in its 2025 share repurchase plan based on optimistic future development prospects [3] Group 3: Market and Clientele - Major clients for the company's pea protein include international giants such as Nestlé, Mars, and DuPont [3] - The company is monitoring trends in the plant-based meat sector, which is expected to have growth potential [3] Group 4: Shareholder Engagement - The company is considering suggestions for online product discount activities for shareholders and evaluating the feasibility of a shareholder ordering program [4] - The company acknowledges the importance of different product development for various demographics and application scenarios [4]